Himala Kashmiri
Pediatric Endocrinology · Orange, CANPI 1386808285
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations.
Across 179 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$653
- AbbVie$426
- Ascendis Pharma Endocrinology Inc$402
- Dexcom, Inc.$396
- Medtronic$365
- Kyowa Kirin, Inc.$290
- plus $3K from 32 others
Across 228 payments — averaging $471.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mannkind Corporation$108K
What the payments were for
- Travel & lodging$1984%
- Food & beverage$4,95995%
- Other$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $653 |
| AbbVie | 20 | $426 |
| Ascendis Pharma Endocrinology Inc | 10 | $402 |
| Dexcom, Inc. | 23 | $396 |
| Medtronic(2 entities) | 10 | $365 |
| Kyowa Kirin, Inc. | 8 | $290 |
| Tandem Diabetes Care, Inc. | 13 | $281 |
| Mannkind Corporation | 3 | $228 |
| Lilly USA, LLC | 10 | $206 |
| Endo Pharmaceuticals Inc. | 2 | $197 |
| Neurocrine Biosciences, Inc. | 6 | $183 |
| Pfizer | 9 | $169 |
| Sanofi-aventis U.S. LLC | 4 | $167 |
| IBSA Pharma Inc. | 1 | $110 |
| Insulet Corporation | 4 | $104 |
| Azurity Pharmaceuticals, Inc. | 4 | $101 |
| Rhythm Pharmaceuticals, Inc. | 4 | $99 |
| Amphastar Pharmaceuticals, Inc. | 4 | $76 |
| Biomarin Pharmaceutical Inc. | 3 | $75 |
| Tolmar, Inc. | 2 | $72 |
| Eton Pharmaceuticals, Inc. | 2 | $70 |
| Arbor Pharmaceuticals, Inc. | 3 | $56 |
| BETA Bionics, Inc. | 3 | $54 |
| Abbott | 1 | $50 |
| Ascensia Diabetes Care US Inc. | 2 | $44 |
| Vistapharm, Inc. | 2 | $38 |
| Tolmar Pharmaceuticals, Inc. | 1 | $38 |
| Aegerion Pharmaceuticals, Inc. | 2 | $32 |
| Embecta Corp. | 1 | $29 |
| Zealand Pharma US, Inc. | 1 | $29 |
| Sequel Med Tech, LLC | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| AstraZeneca | 1 | $23 |
| Galen US Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,206 in reported general payments places this provider in the 75th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Orange
- Lynda PolgreenOrange$167K
- Timothy FlanneryOrange$32K
- Daina DreimaneOrange$3K
- Nikita ForghaniOrange$3K
- Lien TrinhOrange$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Kevin KaisermanWest Covina$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.